Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Accumulated Depreciation: 2019-2021

Historic Accumulated Depreciation for C4 Therapeutics (CCCC) over the last 3 years, with Dec 2021 value amounting to $6.9 million.

  • C4 Therapeutics' Accumulated Depreciation rose 17.77% to $7.2 million in Q1 2022 from the same period last year, while for Mar 2022 it was $7.2 million, marking a year-over-year increase of 17.77%. This contributed to the annual value of $6.9 million for FY2021, which is 22.80% up from last year.
  • Latest data reveals that C4 Therapeutics reported Accumulated Depreciation of $6.9 million as of FY2021, which was up 22.80% from $5.6 million recorded in FY2020.
  • Over the past 5 years, C4 Therapeutics' Accumulated Depreciation peaked at $6.9 million during FY2021, and registered a low of $4.0 million during FY2019.
  • Moreover, its 3-year median value for Accumulated Depreciation was $5.6 million (2020), whereas its average is $5.5 million.
  • Data for C4 Therapeutics' Accumulated Depreciation shows a peak YoY soared of 42.44% (in 2020) over the last 5 years.
  • C4 Therapeutics' Accumulated Depreciation (Yearly) stood at $4.0 million in 2019, then soared by 42.44% to $5.6 million in 2020, then increased by 22.80% to $6.9 million in 2021.